Clinical trial · Interventional
rTMS in Improving Neuropathy in Patients With Stage I-IV Cancer Who Have Received Oxaliplatin Chemotherapy
Repetitive Transcranial Magnetic Stimulation (rTMS) to Treat Oxaliplatin-Induced Neuropathy
NCT03219502CI-TRIAL-00096529active not recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This trial studies how well repetitive transcranial magnetic stimulation (rTMS) works in improving neuropathy due to oxaliplatin chemotherapy in patients with stage I-IV cancer. rTMS is designed to change brain activity by introducing small magnetic impulses to the scalp that encourage the brain to change its activity.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Neoplasm | Malignant Neoplasm | ONTOLOGY_EXACT | 0.90 |
| Neuropathy | — | UNRESOLVED | — |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Best Practice | Other | — | UNRESOLVED |
| Quality-of-Life Assessment | Other | — | UNRESOLVED |
| Questionnaire Administration | Other | — | UNRESOLVED |
| Repetitive Transcranial Magnetic Stimulation | Procedure | — | UNRESOLVED |
| Sham Intervention | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Group I (rTMS)
- description
- Patients undergo rTMS over 30 minutes for 10 sessions over 10 business days.
- interventionNames
- Other: Quality-of-Life Assessment
- Other: Questionnaire Administration
- Procedure: Repetitive Transcranial Magnetic Stimulation
- type
- SHAM_COMPARATOR
- label
- Group II (sham rTMS)
- description
- Patients undergo sham rTMS over 30 minutes for 10 sessions over 10 business days.
- interventionNames
- Other: Quality-of-Life Assessment
- Other: Questionnaire Administration
- Procedure: Sham Intervention
- type
- ACTIVE_COMPARATOR
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with stage I-IV cancers who received oxaliplatin chemotherapy * Understand and read English, sign a written informed consent, and be willing to follow protocol requirements * Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2 * Grade 2 or higher neuropathic symptoms according to the National Cancer Institute's 4 point grading scale * Neuropathic symptoms must be related to chemotherapy (in the opinion of the treating physician) * Patients must have neuropathic symptoms for a minimum of 3 months * No plans to change the type of pain medication (if a patient is on pain medication) * Willing to come to MD Anderson for the therapy sessions Exclusion Criteria: * Patients who are taking any antipsychotic medications * Patients who have evidence of brain metastases or any with any active central nervous system (CNS) disease at their time of entry into the trial * Patients who have ever been diagnosed with bipolar disorder or schizophrenia * Patients who have a history of head injury, focal brain lesions, or known seizure activity * Patients who are withdrawing from drugs * Patients with intracranial implants or a cardiac pacemaker or any device that is not considered magnetic resonance imaging (MRI) safe. Colorectal patients are sometimes prescribed Tramadol to help control the symptoms of CIPN. Tramadol does lower the seizure threshold, however these patients will be considered eligible for the study if they discontinue the drug 48 hours before the baseline and do not use it during the duration of the study
References
Publications (0)
Data not yet available
No reference posted for this study.